Coya Therapeutics (COYA) shares fell nearly 23% in recent Tuesday trading after the company reported results from its phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
The placebo-controlled study evaluated two dosing regimens of subcutaneous low-dose interleukin-2, or IL-2. The trial met its primary and secondary goals for safety and enhancing regulatory T cell, or Treg, populations, respectively, the company said.
The higher total dose group, however, "did not exhibit benefits in exploratory endpoints, underscoring the importance of appropriate IL-2 dosing for maintaining Treg functionality and its associated effects on cerebrospinal fluid biomarkers and cognitive outcomes," the company said.
Exploratory endpoints of the study examined changes in cerebrospinal fluid, Alzheimer's Disease-related biomarkers, and cognitive status, the company added.
Price: 7.87, Change: -2.33, Percent Change: -22.82
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。